Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

In a letter to the patient advocacy group World Duchenne Organization on Monday, Roche (OTCQX:RHHBF) said that the EMA has requested a temporary hold on several clinical trials involving Elevidys ...

Sarepta Therapeutics recently demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company, STAT has learned.

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy Elevidys after a patient death. Read more here.

Sarepta Therapeutics on Sunday said there had been a second reported case of acute liver failure resulting in death after a patient received the company's gene therapy for a rare form of muscular ...

Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.

Sarepta posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates.

Sarepta’s stock jumped more than 30% on Friday following news that the Food and Drug Administration expanded the pool of patients eligible for its Duchenne muscular dystrophy (DMD) drug, Elevidys.

Sarepta Therapeutics celebrated the results of a clinical trial of its Duchenne therapy. The rest of the Duchenne community was more cautious in its enthusiasm.